Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

Abstract

BACKGROUND In phase 2 trials, treatment with the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virologic response in patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3. METHODS We conducted two randomized, phase 3, open-label studies involving… (More)
DOI: 10.1056/NEJMoa1512612

4 Figures and Tables

Topics

  • Blog articles referencing this paper

  • Presentations referencing similar topics